Indica Labs vs PathAI
If your failure mode is buying a workspace whose underlying AI you cannot govern, and scanner freedom matters most, start with Indica Labs. If the algorithms themselves are the thing you are buying, start with PathAI. The split is whether you are purchasing the workspace or the models inside it. Indica is a cleared platform that runs digital primary diagnosis with no AI required at all, and it holds the widest scanner and interoperability freedom in the category. PathAI grades A on AI centrality because the models are the company, and its AIM-MASH tool is the first pathology Drug Development Tool qualified by both the FDA and the EMA, a bar above clearance. The catch on PathAI is ownership: its pending move into Roche puts neutrality toward outside algorithms in question in a way Indica does not face.
- Widest scanner and interoperability freedom in the category: cleared across two scanner manufacturers (Hamamatsu K232833, Leica K252762), DICOM compatible, and able to host outside algorithms, which earns the only A on interoperability among these platforms.
- Broadest cleared scope: authorized for primary diagnosis of surgical pathology slides generally rather than one tumor type, spanning clinical, research, trials, and companion diagnostic work.
- Disciplined regulatory disclosure: states plainly that HALO AP Dx is the cleared product, that HALO AP is research use only, and that clearance is tied to named scanners.
- The AI is the substance, not a feature layered onto a platform: more than 20 validated algorithms and an A on AI centrality, so if model quality is what you are paying for, this is the platform built on it.
- The deepest regulatory pedigree for the algorithms: AIM-MASH is the first pathology Drug Development Tool qualified by both the FDA and the EMA, and the 2025 platform clearance carries a Predetermined Change Control Plan, so model updates follow a path agreed in advance rather than arriving silently.
- Commercial and evidence validation Indica cannot match: a national reference laboratory licensed the platform for its own operations, and Roche agreed to acquire the company for up to roughly 1.05 billion dollars.
Side-by-Side
| Axis | I Indica Labs |
P PathAI |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Neither vendor publishes pricing. PathAI's ownership is in transition through a Roche merger expected to close in the second half of 2026, moving it into Roche's Diagnostics division; external analysts have flagged whether an open algorithm host stays neutral under a diagnostics owner with its own assay pipeline, and buyers should confirm how existing licensing survives the deal. PathAI also publishes no SOC 2, HITRUST, or ISO 27001 attestation, notable because its direct competitor Ibex publishes the full set. Indica couples clearance to specific scanners, so hardware choice and software cost are one decision rather than two, and it documents its own AI models thinly; it states HIPAA compliance but publishes no BAA or security attestation beyond ISO 13485 and 21 CFR Part 11.